NEW YORK, Sept. 20 (GenomeWeb News) - Shares of Sequenom's stock are down 4.88 percent, or $.04, at $.78 today following news this morning that the company has received a delisting warning letter from the Nasdaq exchange.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.